BTI
TGTX icon

Blue Trust Inc’s TG Therapeutics TGTX Stock Holding History

Blue Trust Inc’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7K Sell
194
-116
-37% -$4.75K ﹤0.01% 1851
2026
Q1 		$10.3K Hold
310
– – ﹤0.01% 1835
2025
Q4 		$9.24K Sell
310
-1,197
-79% -$39.1K ﹤0.01% 1883
2025
Q3 		$54.4K Hold
1,507
– – ﹤0.01% 1370
2025
Q2 		$54.2K Sell
1,507
-616
-29% -$22.9K ﹤0.01% 1434
2025
Q1 		$83.7K Buy
2,123
+236
+13% +$7.94K ﹤0.01% 1076
2024
Q4 		$56.8K Buy
1,887
+371
+24% +$10.6K ﹤0.01% 1240
2024
Q3 		$27K Buy
1,516
+849
+127% +$18.5K ﹤0.01% 1830
2024
Q2 		$10.1K Buy
+667
New +$10.6K ﹤0.01% 1922
2023
Q3 		– Sell
-33
Closed – – 2284
2023
Q2 		$0 Sell
33
-28
-46% -$723 ﹤0.01% 2519
2023
Q1 		$0 Sell
61
-35
-36% -$532 ﹤0.01% 2629
2022
Q4 		$1K Sell
96
-12
-11% -$87 ﹤0.01% 2143
2022
Q3 		$0 Buy
+108
New +$708 ﹤0.01% 2324

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Blue Trust Inc's TGTX Position: Q2 2026 in Review

Blue Trust Inc reduced its TG Therapeutics (TGTX) stake by 37% in Q2 2026, selling an estimated $4.75K and leaving 194 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1851.

Blue Trust Inc first reported a position in TGTX in Q3 2022 and has held it in 13 quarters since. The position peaked at $83.7K in Q1 2025. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Blue Trust Inc held 194 shares of TG Therapeutics worth $10.7K as of Q2 2026.
  • Blue Trust Inc sold 116 TG Therapeutics shares in Q2 2026, an estimated $4.75K.
  • TG Therapeutics made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #1851 holding.
  • Blue Trust Inc first reported a position in TG Therapeutics in Q3 2022 and has held it in 13 quarters since.
  • Blue Trust Inc's TG Therapeutics position peaked at $83.7K in Q1 2025.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.